spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  resistant hypertension 

 HSMN NewsFeed - 8 Nov 2023
Recor Medical and Otsuka Medical Devices Announce First FDA-Approved Renal Denervation System for the Treatment of Hypertension
Devices Cardiology FDA
 HSMN NewsFeed - 9 Jan 2023
SoniVie Raises $60m in Round C Financing, and Appoints New Board Members
Devices Venture Capital
 HSMN NewsFeed - 13 Jul 2022
SoniVie Announces successful procedure with TIVUS system on first patient enrolled for REDUCED1 Pilot study
Devices
 HSMN NewsFeed - 18 May 2021
Late Breaking Data at EuroPCR Demonstrates Long-Term Benefits of Medtronic Radiofrequency Renal Denervation in Real-World Hypertensive Patients
Devices Interventional Cardiology
 HSMN NewsFeed - 10 Dec 2020
ReCor Medical Announces Positive Results in RADIANCE-HTN TRIO Study and Breakthrough Device Designation for Paradise(TM) Ultrasound Renal Denervation System
Devices Cardiology FDA
 HSMN NewsFeed - 9 Dec 2019
Windtree Therapeutics Completes $26.4 Million Private Placement
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 23 May 2018
ReCor Medical Announces RADIANCE-HTN SOLO Hypertension Study Meets Primary Efficacy Endpoint, Pivotal Study Submission, and New Principal Investigator
Devices Cardiology
 HSMN NewsFeed - 26 Mar 2018
Pythagoras Medical Receives CE-Mark for the ConfidenHT(TM) System
Devices Cardiology Regulatory
 HSMN NewsFeed - 16 Jun 2017
Johnson & Johnson Announces Completion of Acquisition of Actelion
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 31 Oct 2016
ReCor Medical Announces Key Milestones in RADIANCE-HTN Hypertension Clinical Study
Devices Cardiology
 HSMN NewsFeed - 26 Oct 2016
Valencia Technologies' eCoin to be Showcased at TCT 2016 Both for its Premiere Presentation of First-in-Human Clinical Trial Results and as a Novel Hypertension Therapy
Devices Cardiology Neurology
 HSMN NewsFeed - 9 Aug 2016
CVRx(R) Secures $113 Million in New Financing
Devices Venture Capital
 HSMN NewsFeed - 6 Jan 2016
Vascular Dynamics’ MobiusHD(TM) System Receives CE Mark for the Treatment of Resistant Hypertension
Devices Cardiology Regulatory
 HSMN NewsFeed - 19 Nov 2015
CVRx(R) Announces Expedited Access Pathway Designation By FDA for Barostim Therapy(R) for the Treatment Of Heart Failure In Order To Accelerate Access for US Patients
Devices Cardiology FDA
 HSMN NewsFeed - 26 May 2015
CVRx(R) Barostim Therapy(R) for Heart Failure Clinical Trial Results Presented in the Late-Breaking Clinical Trial Session of the Heart Rhythm Society 2015 Annual Conference
Devices Cardiology
 HSMN NewsFeed - 17 Mar 2015
CVRx(R) Barostim Therapy(TM) for Heart Failure Clinical Trial Results Presented in a Featured Clinical Research Session of the American College of Cardiology Annual Conference
Devices Cardiology
 HSMN NewsFeed - 8 Jan 2015
Vascular Dynamics Inc. Secures $16.85 Million Series B Financing
Devices Venture Capital
 HSMN NewsFeed - 16 Dec 2014
CVRx(R) Granted Humanitarian Device Exemption Approval from FDA for Barostim neo legacy(TM) Hypertension Therapy Device
Devices Cardiology FDA
 HSMN NewsFeed - 11 Dec 2014
CVRx(R) Granted CE Marking of the Barostim neo System(TM) for Conditional MRI Compatibility
Devices Cardiology Regulatory
 HSMN NewsFeed - 10 Sep 2014
Afferent Pharmaceuticals Names Kathleen Sereda Glaub as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 May 2014
Preliminary Results From the St. Jude Medical EnligHTN III Study Demonstrate Renal Denervation Is Safe and Effective
Devices Cardiology
 HSMN NewsFeed - 21 Feb 2014
Cordis Corporation Receives CE Mark for RENLANE(TM) Renal Denervation System to Treat Resistant Hypertension
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 28 Jan 2014
ReCor Medical Announces Major Advances with Its Ultrasound-Based Renal Denervation System
Devices Interventional Cardiology
 HSMN NewsFeed - 9 Jan 2014
Medtronic Announces U.S. Renal Denervation Pivotal Trial Fails to Meet Primary Efficacy Endpoint While Meeting Primary Safety Endpoint
Devices Cardiology
 HSMN NewsFeed - 7 Jan 2014
Barostim Therapy(TM) Projected to be Cost-Effective in Treating Resistant Hypertension
Devices Cardiology
 HSMN NewsFeed - 18 Dec 2013
Medtronic Randomizes First Patients in SYMPLICITY HTN-4, the First U.S. Renal Denervation Clinical Study for Patients with Moderate Uncontrolled Hypertension
Devices Interventional Cardiology
 HSMN NewsFeed - 5 Dec 2013
Medtronic Announces CE Mark and TGA Listing for the Symplicity Spyral(TM) Multi-Electrode Catheter and Symplicity G3(TM) Generator
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 21 Oct 2013
Kona Medical Closes $10 Million Financing
Devices Cardiology Venture Capital
 HSMN NewsFeed - 29 Aug 2013
St. Jude Medical Receives European Approval for New Renal Denervation System That Reduces Total Ablation Time by More Than 80 Percent
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 4 Jun 2013
St. Jude Medical Initiates First US Clinical Study of the EnligHTN Renal Denervation System for Drug-Resistant High Blood Pressure
Devices Cardiology Interventional
 HSMN NewsFeed - 23 May 2013
Six Month Data Reported for WAVE I Study of Renal Denervation Therapy for Hypertension at EuroPCR Meeting in Paris
Devices Cardiology
 HSMN NewsFeed - 23 May 2013
One Year Data from St. Jude Medical Study Demonstrates Safe, Rapid and Sustained Blood Pressure Reduction with EnligHTN Renal Denervation Technology
Devices Cardiology
 HSMN NewsFeed - 14 May 2013
St. Jude Medical Announces First Patient Enrollment in EnligHTN III Renal Denervation Study of Next-Generation EnligHTN System
Devices Interventional Cardiology
 HSMN NewsFeed - 7 Mar 2013
Symplicity(TM) Renal Denervation System One of First Devices Accepted to Participate in Concurrent Review for Joint FDA Premarket Approval and Medicare National Coverage Determination
Devices Interventional Cardiology Reimbursement FDA
 HSMN NewsFeed - 4 Dec 2012
Kona Medical Closes $40 Million Financing
Devices Cardiology Venture Capital
 HSMN NewsFeed - 28 Aug 2012
Renal Denervation Technology from St. Jude Medical Demonstrates Safe, Rapid and Sustained Reduction in Blood Pressure
Devices Cardiology
 HSMN NewsFeed - 30 May 2012
Kona Medical Secures $30M in Financing to Pursue Novel Hypertension Therapy
Devices Cardiology Venture Capital Personnel
 HSMN NewsFeed - 16 May 2012
Renal Denervation Technology from St. Jude Medical Demonstrates Significant Reduction in Blood Pressure
Devices Cardiology
 HSMN NewsFeed - 15 May 2012
St. Jude Medical Announces European Approval and Launch of the EnligHTN Renal Denervation System for Treatment of Hypertension
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 14 May 2012
ReCor Medical Completes REDUCE Pilot Clinical Study of Its PARADISE(TM) Ultrasound Transcatheter Renal Denervation System for Treating Resistant Hypertension
Devices Interventional Cardiology
 HSMN NewsFeed - 8 May 2012
Covidien Introduces New Treatment for Drug-Resistant Hypertension
Devices Cardiology
 HSMN NewsFeed - 1 May 2012
Vessix Receives CE Mark For V2 Renal Denervation System(TM) For Treatment Of Hypertension
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 27 Apr 2012
Trial of Medtronic Symplicity(TM) Renal Denervation System Shows Significant Blood Pressure Reduction, With No Evidence of Renal Impairment, at Six Months Post Treatment
Devices Interventional Cardiology
 HSMN NewsFeed - 12 Apr 2012
Vessix Vascular Names Michael D. Gioffredi Chief Commercialization Officer
Devices Personnel
 HSMN NewsFeed - 20 Feb 2012
ReCor Medical Announces CE Mark Approval for Its Novel PARADISE(TM) Ultrasound Transcatheter Renal Denervation System
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 13 Feb 2012
Medtronic Launches Two New Clinical Programs to Evaluate the Use of Symplicity(TM) 1 Renal Denervation System across Multiple Conditions
Devices Cardiology
 HSMN NewsFeed - 7 Nov 2011
Vascular Dynamics Names Former Micrus Endovascular President Robert Stern as President and CEO
Devices Personnel
 HSMN NewsFeed - 4 Nov 2011
Medtronic’s Unmatched Portfolio of Cardiovascular Devices Features Prominently on Program for TCT 2011
Devices Interventional Cardiology
 HSMN NewsFeed - 17 Oct 2011
St. Jude Medical Announces First Use of Renal Denervation Technology
Devices
 HSMN NewsFeed - 25 Aug 2011
CVRx(R) Receives CE Mark Approval and Introduces New Implantable Device for Hypertension, the Barostim neo(TM)
Devices Cardiology Regulatory
 HSMN NewsFeed - 2 Dec 2010
PhaseBio Pharmaceuticals Reaches Key Milestones and Receives $15 Million to Complete Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 21 Jun 2010
Four-Year Clinical Study Findings Show Significant and Persistent Reduction in Blood Pressure with Rheos(R) System
Devices
 HSMN NewsFeed - 9 Nov 2009
VIVA 2009 Late-Breaking Trials Highlight Advances in Interventional Treatments of Peripheral Arterial Disease
Devices Interventional
 HSMN NewsFeed - 30 Mar 2009
Longer-Term Clinical Trial Findings Show Significant Reduction in Blood Pressure, Improvement in Heart Function with CVRx Rheos System
Devices Cardiology
 HSMN NewsFeed - 31 Oct 2007
CVRx(R), Inc. Receives CE Mark Approval for Rheos(R) Baroreflex Hypertension Therapy(TM) System
Devices Cardiology FDA
 HSMN NewsFeed - 11 Jul 2007
Medical Device Company CVRx Adopts Configurable ARC(R) Core For Implantable Blood Pressure Reduction Device
Devices Cardiology
 HSMN NewsFeed - 25 Jun 2007
Encysive Pharmaceuticals Appoints New Chief Executive and Announces Restructuring of Company Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Jun 2007
CardioDynamics Announces New ICG Hypertension Evidence
Devices Monitoring Cardiology
 HSMN NewsFeed - 17 May 2007
CVRx(R), Inc. Appoints Todd Langevin Senior Vice President of Clinical and Commercial Development
Devices Personnel
 HSMN NewsFeed - 25 Mar 2007
European and U.S. Clinical Trial Findings Show Significant Reduction in Blood Pressure with CVRx(R) Rheos(TM) Baroreflex Hypertension Therapy(TM) System
Devices Cardiology
 HSMN NewsFeed - 16 Oct 2006
CVRx(R), Inc., Receives IDE Approval for Rheos(TM) Baroreflex Hypertension Therapy(TM) System Pivotal Trial
Devices FDA
 HSMN NewsFeed - 2 Oct 2006
Gilead Sciences to Acquire Myogen, Inc. for $2.5 Billion
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 7 Sep 2006
Myogen Initiates Open-Label Phase 3 Clinical Trial of Ambrisentan in Patients with Pulmonary Hypertension
Biopharmaceuticals
 HSMN NewsFeed - 24 May 2006
Ambrisentan Phase 3 ARIES-2 PAH Data Presented At ATS 2006 -- San Diego
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 18

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 18 additional stories matching:
resistant hypertension
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.